Trial Profile
An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 >= 250 Cells/mm3 and HIV Virus Load >= 50,000 cp/mL
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz; Emtricitabine; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate; Zidovudine
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 17 May 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov record.
- 30 Apr 2012 New trial record